Synaffix Awarded "Runner Up" Postion for Best Platform ADc Technology
World ADC is pleased to announce the finalists in the 4th Annual World ADC Awards. The World ADC Awards showcase the innovation, leadership and devotion shown by the best companies, teams and individuals in the industry. Across 9 categories the Awards will recognise the extraordinary endeavours, teamwork and commercial acumen that has propelled the field to the forefront of cancer research today.
San Diego, CA, September 24, 2017 –(PR.com)– The 4th Annual World ADC Awards Ceremony took place the evening of September 21 at the Sheraton San Diego Marina at 7:15pm.
The Awards are sponsored by Abbvie (Headline Sponsor), Immunogen (Long Standing Contribution to the Field), Ambrx (Best ADC Platform Technology) and Medimmune (Best Publication 2016).
The Awardees were shortlisted from over 1600 votes cast and scientific proposals from each submission were evaluated by our Judging panel.
Fiona Mistri, Program Director, World ADC San Diego stated, “Every year the judges are impressed with the level of innovation and scientific breakthroughs that these companies are driving. This year is no exception and we are delighted to see the calibre and quantity of entries – showing the growing momentum and advances being made within the industry.”
Jagath Reddy Junutula, Cellerent Therapeutics and judge of the Awards said, “The World ADC Awards showcase excellence within the antibody-drug conjugate (ADC) field. This year’s winners represent once again the dedication, leadership and innovation that exists in this crucial area of oncology therapeutics. These Awards shine a spotlight on these companies leading the field and as a judge once again I was delighted to see the growing momentum and progress within the field.”
Best Platform Technology (sponsored by Ambrx)
Winner: Bicycle Therapeutics
Runner Up: Synaffix BV
Most Promising Clinical Candidate
Winner: ImmunoGen (Mirvetuximab soravtansine)
Runner Up: Stemcentrx (Rova-T)
Best CMO Provider
Runner Up: BSP Pharmaceuticals
Best New Drug Developer
Runner Up: Heidelberg Pharma
Best CRO Provider
Runner Up: SynGene
Best Publication 2016 (sponsored by Medimmune)
Winner: A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR. Cancer Cell. 2016 Jan 11;29(1):117-29. doi: 10.1016/j.ccell.2015.12.008.
Runner Up: Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Staben LR1, Koenig SG1, Lehar SM1, Vandlen R1, Zhang D1, Chuh J1, Yu SF1, Ng C1, Guo J1, Liu Y1, Fourie-O’Donohue A1, Go M1, Linghu X1, Segraves NL1, Wang T2, Chen J2, Wei B1, Phillips GD1, Xu K1, Kozak KR1, Mariathasan S1, Flygare JA1, Pillow TH1. Nat Chem. 2016 Dec;8(12):1112-1119. doi: 10.1038/nchem.2635.
Individual Input to the Field 2016
Long Standing Contribution
Jagath Reddy Junutula
For more information about the World ADC Awards visit worldadc-awards.com
About World ADC San Diego
Focused on ADCs and crafted with the field’s thought-leaders, World ADC is the industry’s definitive forum for learning and networking.